WEP Clinical (WEP) is pleased to announce our partnership with Pharming Group N.V. ("Pharming" EURONEXT Amsterdam: PHARM/Nasdaq: PHAR), a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and [...]
WEP Clinical Inc. (WEP) is pleased to announce that it has partnered with Sellas Life Sciences Group, Inc. (“Sellas”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for various cancer [...]
WEP Clinical (WEP), a specialist services company that works with sponsors to help patients and physicians gain early access to medicines when no other treatment options are available, has appointed Karl Challender as the [...]
WEP Clinical (WEP) today announced a partnership with Horizon Therapeutics plc (Horizon) to make a Named Patient Use (NPU) Program available for UPLIZNA. The UPLIZNA NPU Program is for adult patients who are AQP4-IgG+ [...]
